Definition of remission, minimal residual disease, and relapse in hairy cell leukemia bone marrow biopsy histology and immunohistology specimens.

Pierre Noel

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

No consensus has been reached in the definitions of complete remission (CR) and minimal residual disease (MRD) on bone marrow biopsy specimens of patients with hairy cell leukemia (HCL). Large comparative studies correlating clinical outcome with detection of MRD by immunohistochemistry (IHC), flow cytometry, and molecular diagnostics are lacking. The presence of normal bone marrow B-lymphocytes and the lack of immunohistochemical stains that are both sensitive and specific can make it challenging to differentiate normal lymphocytes from hairy cells. The use of CD20 and/or DBA.44 immunohistochemical stains, in combination with either tartrate resistant acid phosphatase (TRAP), CD11c-5D11, or annexin A1, improve specificity and facilitate evaluation. The interobserver concordance in quantifying the percentage of residual hairy cells is poor. Performing cell counts in multiple fields improves reproducibility. The prolonged hematologic remissions of subsets of patients with MRD emphasize the need to define clinically relevant thresholds that correlate with long-term responses and clinical endpoints. The development of internationally accepted, reproducible, and clinically relevant CR, MRD, and relapse criteria are of paramount importance in evaluating and comparing clinical trials and in providing optimal patient care.

Original languageEnglish (US)
Pages (from-to)62-64
Number of pages3
JournalLeukemia & lymphoma
Volume52 Suppl 2
DOIs
StatePublished - Jun 2011

Fingerprint

Hairy Cell Leukemia
Residual Neoplasm
Histology
Bone Marrow
Biopsy
Recurrence
Coloring Agents
Annexin A1
Molecular Pathology
Patient Care
Flow Cytometry
B-Lymphocytes
Cell Count
Immunohistochemistry
Clinical Trials
Lymphocytes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Definition of remission, minimal residual disease, and relapse in hairy cell leukemia bone marrow biopsy histology and immunohistology specimens. / Noel, Pierre.

In: Leukemia & lymphoma, Vol. 52 Suppl 2, 06.2011, p. 62-64.

Research output: Contribution to journalArticle

@article{22b618099b514899b0134485f536db79,
title = "Definition of remission, minimal residual disease, and relapse in hairy cell leukemia bone marrow biopsy histology and immunohistology specimens.",
abstract = "No consensus has been reached in the definitions of complete remission (CR) and minimal residual disease (MRD) on bone marrow biopsy specimens of patients with hairy cell leukemia (HCL). Large comparative studies correlating clinical outcome with detection of MRD by immunohistochemistry (IHC), flow cytometry, and molecular diagnostics are lacking. The presence of normal bone marrow B-lymphocytes and the lack of immunohistochemical stains that are both sensitive and specific can make it challenging to differentiate normal lymphocytes from hairy cells. The use of CD20 and/or DBA.44 immunohistochemical stains, in combination with either tartrate resistant acid phosphatase (TRAP), CD11c-5D11, or annexin A1, improve specificity and facilitate evaluation. The interobserver concordance in quantifying the percentage of residual hairy cells is poor. Performing cell counts in multiple fields improves reproducibility. The prolonged hematologic remissions of subsets of patients with MRD emphasize the need to define clinically relevant thresholds that correlate with long-term responses and clinical endpoints. The development of internationally accepted, reproducible, and clinically relevant CR, MRD, and relapse criteria are of paramount importance in evaluating and comparing clinical trials and in providing optimal patient care.",
author = "Pierre Noel",
year = "2011",
month = "6",
doi = "10.3109/10428194.2011.565098",
language = "English (US)",
volume = "52 Suppl 2",
pages = "62--64",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Definition of remission, minimal residual disease, and relapse in hairy cell leukemia bone marrow biopsy histology and immunohistology specimens.

AU - Noel, Pierre

PY - 2011/6

Y1 - 2011/6

N2 - No consensus has been reached in the definitions of complete remission (CR) and minimal residual disease (MRD) on bone marrow biopsy specimens of patients with hairy cell leukemia (HCL). Large comparative studies correlating clinical outcome with detection of MRD by immunohistochemistry (IHC), flow cytometry, and molecular diagnostics are lacking. The presence of normal bone marrow B-lymphocytes and the lack of immunohistochemical stains that are both sensitive and specific can make it challenging to differentiate normal lymphocytes from hairy cells. The use of CD20 and/or DBA.44 immunohistochemical stains, in combination with either tartrate resistant acid phosphatase (TRAP), CD11c-5D11, or annexin A1, improve specificity and facilitate evaluation. The interobserver concordance in quantifying the percentage of residual hairy cells is poor. Performing cell counts in multiple fields improves reproducibility. The prolonged hematologic remissions of subsets of patients with MRD emphasize the need to define clinically relevant thresholds that correlate with long-term responses and clinical endpoints. The development of internationally accepted, reproducible, and clinically relevant CR, MRD, and relapse criteria are of paramount importance in evaluating and comparing clinical trials and in providing optimal patient care.

AB - No consensus has been reached in the definitions of complete remission (CR) and minimal residual disease (MRD) on bone marrow biopsy specimens of patients with hairy cell leukemia (HCL). Large comparative studies correlating clinical outcome with detection of MRD by immunohistochemistry (IHC), flow cytometry, and molecular diagnostics are lacking. The presence of normal bone marrow B-lymphocytes and the lack of immunohistochemical stains that are both sensitive and specific can make it challenging to differentiate normal lymphocytes from hairy cells. The use of CD20 and/or DBA.44 immunohistochemical stains, in combination with either tartrate resistant acid phosphatase (TRAP), CD11c-5D11, or annexin A1, improve specificity and facilitate evaluation. The interobserver concordance in quantifying the percentage of residual hairy cells is poor. Performing cell counts in multiple fields improves reproducibility. The prolonged hematologic remissions of subsets of patients with MRD emphasize the need to define clinically relevant thresholds that correlate with long-term responses and clinical endpoints. The development of internationally accepted, reproducible, and clinically relevant CR, MRD, and relapse criteria are of paramount importance in evaluating and comparing clinical trials and in providing optimal patient care.

UR - http://www.scopus.com/inward/record.url?scp=79961113125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961113125&partnerID=8YFLogxK

U2 - 10.3109/10428194.2011.565098

DO - 10.3109/10428194.2011.565098

M3 - Article

VL - 52 Suppl 2

SP - 62

EP - 64

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

ER -